熱門資訊> 正文
DiaMedica Therapeutics GAAP每股收益为-0.18美元在线
2025-05-14 15:25
- DiaMedica Therapeutics press release (NASDAQ:DMAC): Q1 GAAP EPS of -$0.18 in-line.
- Cash Position and Runway – Cash, cash equivalents and short-term investments were $37.3 million as of March 31, 2025, compared to $44.1 million as of December 31, 2024. Based on its current plans, the Company anticipates its current cash, cash equivalents and short-term investments will enable the Company to fund its planned clinical studies and support corporate operations into the third quarter of 2026.
- Net cash used in operating activities for the quarter ended March 31, 2025 was $7.1 million compared to $6.7 million for the same period in 2024.
More on DiaMedica Therapeutics
- DiaMedica Therapeutics: Stroke Developer With Low Cash Reserve
- DiaMedica Therapeutics Inc. (DMAC) Q4 2024 Earnings Call Transcript
- DiaMedica Therapeutics GAAP EPS of -$0.60 misses by $0.01
- Seeking Alpha’s Quant Rating on DiaMedica Therapeutics
- Historical earnings data for DiaMedica Therapeutics
推薦文章
美股機會日報丨關税大消息！涉及歐盟、日本；科技巨頭財報夜：谷歌、特斯拉能否攪動市場情緒？
特朗普即將揭曉「AI行動計劃」，這些美股有望贏政策利好，誰將從中「分羹」？
美股異動丨英偉達、博通跌超3%，穩定幣巨頭Circle跌超7%
美股機會日報丨鮑威爾發言在即！散户瘋炒，「Meme股」OPEN盤前漲超23%
特朗普媒體公司囤積20億美元比特幣！加密貨幣推動特朗普淨資產大幅增長
AI和機器人有望刺激特斯拉股價？財報季提前部署期權策略
華盛早報丨科技「七巨頭「財報來襲定調美股走向！金融科技公司Block獲入標普500指數
美股「七巨頭」迎特朗普關稅后首次大考！Q2能否交出亮眼成績單，繼續引領美股上漲？
風險及免責提示：以上內容僅代表作者的個人立場和觀點，不代表華盛的任何立場，華盛亦無法證實上述內容的真實性、準確性和原創性。投資者在做出任何投資決定前，應結合自身情況，考慮投資產品的風險。必要時，請諮詢專業投資顧問的意見。華盛不提供任何投資建議，對此亦不做任何承諾和保證。
